Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2018-12-03 Director's Dealing
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Updates
Director's Dealing Classification · 95% confidence The document is a disclosure under the Securities and Exchange Board of India (SEBI) regulations regarding insider trading, specifically reporting the acquisition of shares by a promoter of the company. It includes details such as the number of shares acquired, the date of acquisition, and the name of the promoter. This type of filing is a notification of a director's or promoter's personal share transactions, which fits the definition of Director's Dealing (DIRS). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure of insider share transactions.
2018-12-03 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (70 characters) and contains no substantive content, only placeholders and an omitted picture note. There is no financial data, no report content, no announcements, or any regulatory information. Given the lack of content, this cannot be classified as any substantive report or announcement. According to the rules, such minimal content defaults to Regulatory Filings (RNS) as a fallback category.
2018-11-05 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document contains a detailed announcement of the Board Meeting outcome of Beta Drugs Limited held on 26th October 2018. It specifically mentions the approval of unaudited financial results for the half year ended 30th September 2018 along with a limited review report as per SEBI regulations. The text includes management discussion and analysis (MD&A) of the half-year financial performance, and a limited review report by the auditors, which is a standard practice for interim or quarterly financial reporting. The presence of half-year financial results, management discussion, and auditor's limited review strongly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2018-10-26 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document contains a detailed management discussion and analysis section discussing financial results for the half year ended September 30, 2018. It also includes a limited review report by the auditors pursuant to SEBI regulations for the half year ended September 30, 2018. The presence of unaudited financial results, management commentary, and auditor's limited review report indicates this is a comprehensive interim financial report for a period shorter than a full fiscal year. The document is about 15,000 characters long, which is consistent with a full interim report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2019
2018-10-26 English
Updates
Regulatory Filings Classification · 95% confidence The document is a news article reporting on a business development involving an Indian pharmaceutical company starting production in Uzbekistan. It contains no financial data, regulatory references, or corporate filings. It is not a report, announcement of a report, or any regulatory filing. It is purely informational news content about a joint venture and production plans.
2018-10-20 English
Updates
M&A Activity Classification · 95% confidence The document text primarily discusses details about the acquisition of a new subsidiary, Beta Ubk International Private Limited, including shareholding percentages, authorized share capital, and business operations. It includes information about the nature of the acquisition, consideration (cash), and background of the acquired entity. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. The content focuses on the acquisition transaction details, which aligns with announcements related to mergers and acquisitions. The document length is short (3048 characters) and contains detailed acquisition information rather than just an announcement of a report or a brief notice. Therefore, the most appropriate classification is M&A Activity (TAR).
2018-10-18 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.